ermp case 21- sglt2 inhibitors
Published 12 days ago • 108 plays • Length 18:13Download video MP4
Download video MP3
Similar videos
-
7:17
medical case discussion # 23 - primary prevention of arteriosclerotic cardiovascular diseases
-
0:30
sglt2 inhibitors for diabetics
-
20:13
sglt2 inhibitors in heart failure management with dr. john mcmurray
-
2:59
assimilating the evidence in t2dm: cardiovascular and renal outcomes with sglt2 inhibitors
-
6:21
ada 2018: sglt2 inhibitors in the management of type 2 diabetes
-
27:44
are there alternative mechanisms to explain sglt2i beneficial cveffects in some patients?
-
6:57
how does dapagliflozin work? understanding sglt2 inhibitors.
-
1:14
case scenario 2 - combination basal insulin glp-1ra therapy
-
16:08
sglt-2 inhibitors - place in therapy for dm type 2
-
5:07
sglt2 inhibitors are associated with reduced cv disease in type 2 diabetes
-
2:27
sglt2 inhibitors in t2dm
-
4:34
sglt2 inhibitor treatment considerations
-
22:15
sglt-2 inhibitors for type 2 diabetes - amel arnaout, md
-
11:01
why sglt2 inhibitors cause euglycemic dka
-
2:09
is one sglt2 (or glp-1) just like another for cardiac benefit?
-
50:39
is type 2 diabetes reversible? 9 november 2021
-
29:46
sglt2i in different patient groups: effect on ckd progression | natalie staplin, phd